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Abstract
Purpose Through a European-wide survey, we assessed the current clinical practice of imaging in the primary evaluation of
dementia, with respect to standardised imaging, evaluation and reporting.
Methods An online questionnaire was emailed to all European Society of Neuroradiology (ESNR) members (n = 1662) and non-
members who had expressed their interest in ESNR activities in the past (n = 6400). The questionnaire featured 42 individual
items, divided into multiple choice, single best choice and free text answers. Information was gathered on the context of the
practices, available and preferred imaging modalities, applied imaging protocols and standards for interpretation, reporting and
communication.
Results A total of 193 unique (non-duplicate) entries from the European academic and non-academic institutions were received
from a total of 28 countries. Of these, 75% were neuroradiologists, 12% general radiologists and 11% (neuro) radiologists in
training. Of responding centres, 38% performed more than five scans/week for suspected dementia. MRI was primarily used in
72% of centres. Over 90% of centres acquired a combination of T2w, FLAIR, T1w, DWI and T2*w sequences. Visual rating
scales were used in 75% of centres, most often the Fazekas and medial temporal atrophy scale; 32% of respondents lacked full
confidence in their use. Only 23% of centres performed volumetric analysis. A minority of centres (28%) used structured reports.
Conclusions Current practice in dementia imaging is fairly homogeneous across Europe, in terms of image acquisition and image
interpretation. Hurdles identified include training on the use of visual rating scales, implementation of volumetric assessment and
structured reporting.
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Introduction
Worldwide populations are ageing, with an accompanying
increase in prevalence of cognitive problems and dementia.
At present, 50 million people worldwide are living with de-
mentia, of whom the majority with Alzheimer’s disease as its
most common subtype, and this number is predicted to double
every 20 years to reach over 130 million by 2050 [1].
Nowadays, brain imaging plays a key role in the diagnosis
and evaluation of patients suspected of dementia. Structural
imaging, either with computed tomography (CT) or magnetic
resonance imaging (MRI), is recommended at least once in the
diagnostic workup of patients with cognitive impairment [2].
Whereas these exams initially served the goal to exclude al-
ternative causes of dementia than neurodegeneration, which
are potentially treatable (e.g. subdural hematomas or brain
tumours), progressive insight has led to a role of imaging
markers to help establish a positive diagnosis of dementia
subtype. The latter is of increasing importance in light of
prognosis, disease-modifying therapies and emerging treat-
ment options. In particular, patterns of cerebral atrophy (in-
cluding hippocampal atrophy) and presence and burden of
vascular lesions can point towards a specific underlying diag-
nosis [3, 4]. This is reflected by the inclusion of neuroimaging
markers into the diagnostic and research criteria for
Alzheimer’s disease [5–7] and for vascular dementia [8, 9].
As a result of the above, radiologists both in academic and
in non-academic centres are increasingly confronted with
scans from patients evaluated at memory clinics. Yet, guide-
lines or recommendations on how to best manage the imaging,
interpretation and reporting in this patient group are virtually
non-existent [2]. Some clinical textbooks have published a
proposed minimum set of MR imaging criteria for the evalu-
ation of memory clinic patients [3, 4], consisting of 3D T1-
weighted imaging, fluid-attenuated inversion recovery
(FLAIR), turbo-spin or fast-spin T2-weighted images,
diffusion-weighted images (DWI) and T2*-weighted
gradient-recalled echo (GRE) imaging. Yet, to what extent
such a suggested protocol is feasible and actually applied in
clinical settings is largely unknown. For the interpretation of
patterns of atrophy and vascular burden, several semi-
quantitative visual rating scales have been reported [10–13] and
validated [14, 15]. Again, whether these are actually used in
everyday clinical practice across Europe also remains uncertain.
Apart from conventional structural neuroimaging, there is a
large body of recent research into the use of advanced imaging
markers derived from perfusion imaging (e.g. arterial spin label-
ling (ASL)), functional imaging (fMRI) or tissue microstructure
(diffusion tensor imaging) for early detection of dementia or
those at risk to develop to disease [16]. Also, developments
are made to use quantitative information such as volumetric
measures as potential diagnostic markers [17]. If such markers
are expected to be implemented into clinical practice, it is useful
to gauge the acceptance within the clinical community and po-
tential hurdles associated with implementation.
In a recent survey conducted among memory clinics in the
Netherlands, 75% of respondents reported that no standardised
assessment of acquired images was performed [18]. This is in
contradiction with the growing role of imaging in subtyping
dementia, assessing diagnosis earlier and the inclusion of pa-
tients in clinical trials. The European Society of Neuroradiology
(ESNR) therefore sought to assess the current clinical practice
of imaging in the primary evaluation of dementia and determine
potential hurdles to act upon. To this end, a working group was
established which mapped the current landscape using a pan-
European survey distributed among ESNR members and affil-
iates, addressing the context of the practices available and pre-
ferred imaging modalities, applied imaging protocols (includ-
ing use of advanced imaging) and standards for interpretation,
reporting and communication. The results of this survey as well
as conclusions by the working group are reported in this
manuscript.
European survey on dementia imaging
Methods
An online questionnaire was designed using Google forms open-
access toolbox (Google.com, Mountain View, CA, USA).
Questions were assembled by the members of the ESNR
Working Group (authors MWV, FBP, FB, SH) and further
modified/added by the ESNR Diagnostic Committee (MWV,
TY, MS, NB) as well as by 2 members of the European
Association of Neurology (EAN) committee (GF and RS, the
latter acting as co-chair of the Panel of Dementia and Cognitive
Disorders of the EAN). The questionnaire featured 42 items,
divided into multiple choice, single best choice and free text
questions on personal practice as well as clinical scenarios (see
supplement for entire list of questions).
Survey invitations were emailed to all ESNR members
(n = 1662) and non-members who had expressed their interest
in ESNR activities in the past (n = 6400), European national
neuroradiological societies (the UK, the Netherlands,
Belgium, Turkey), and distributed via professional social me-
dia channels (LinkedIn, Twitter, Facebook). The survey was
open for 2 months from 1 May to 1 July 2017. To avoid
duplicate bias, participants were instructed to supply institu-
tion details or confirm they were the only person answering
from their centre.
A number of questions included the option ‘other’. If this
was answered by < 5% of individuals, percentages are not
quoted in the results.
The results of the survey were presented by the members of
the working group at the 2017 annual meeting of the ESNR in
Malmo in a dedicated session that was attended by around a
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hundred meeting participants. Matters arising in the plenary
discussion of that session were considered when interpreting
survey results and formulating conclusions and discussed fur-
ther with the EAN representatives.
Results
Demographic data and set-up of practice
A total of 193 unique (non-duplicate) entries from European
institutions were received from a total of 28 countries.
Figure 1 shows a map of the distribution of responses per
country. Countries with most participating institutions were
the Netherlands (n = 22), the UK (19), Spain (18),
Switzerland (17), Germany (15), Italy (14) and Turkey (14).
Among the 193 respondents, 75% were neuroradiologists,
12% worked as general radiologists and 11% were still in
training. Of all respondents, 115 (59.6%) worked in academic
hospitals, 66 (34.2%) in general hospitals, 27 in private prac-
tice (14.0%), 7 in memory clinics and 3 in other centres (note
that multiple answers were possible to this question).
When we restricted the analysis to respondents who
worked only in academia or in a non-academic setting (gen-
eral hospital or private practice) (n = 173), 101 of those (58%)
worked in academia and 72 (42%) in a non-academic setting.
This sample excluded respondents (n = 20) who worked in
both settings. We used this sample to stratify several of the
analyses for an academic versus non-academic setting, to
study whether important differences between both settings
existed.
Specific memory clinics to evaluate patients were present
in 121 (62.7%) of all institutions. This number was lower for
general hospitals (48.6%) compared to academic institutions
(71.3%). Patients were being referred for dementia evaluation
primarily by neurologists (39.4%) and primary care providers
(34.2%) (Fig. 2).
Of the 193 responding institutes, 38.3% performed more
than five scans for the initial evaluation of dementia per week
and 48.2% performed one to five scans per week (Fig. 3).
These proportions did not differ significantly between aca-
demic centres and non-academic institutions, but scan num-
bers were slightly higher in academia (e.g. 43.6 vs. 34.7%
performed > 5 scans per week).
Imaging modalities
Imaging modalities available in the 193 responding institutes
wereMRI (99.5%), CT (91.2%), single-photon emission com-
puted tomography (SPECT) (either perfusion or dopamine
transporter (DAT) scan) (47.7%), positron emission tomogra-
phy (PET) (40.4%), PET-CT (43%) and PET-MRI (10.9%).
The primary imaging modality used for evaluation of pa-
tients suspected of dementia was CT in 49 (25.4%) of all
institutions and MRI in 138 (71.5%). The remainder of
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Fig. 1 Institutional responses (number) per country. Countries with no responses are shaded grey
institutions used both modalities equally (1.5%) or used MRI
primarily in persons under the age of 65 years and CT in those
who are older (1%). Non-academic institutions had a slightly
stronger tendency towards MRI as primary modality than ac-
ademic centres (73.6 versus 67.3%).
The 49 centres who used CT as primary modality did so
mainly because of shorter wait time (73.5%) and lower costs
(65.3%) and/or because CTwas considered sufficient to answer
the clinical questions (40.8%); only 8 (16.3%) of these 49 cen-
tres did not have access to MRI (multiple answers possible).
Fig. 3 Caseload per centre for
initial diagnosis of dementia
Fig. 2 Referral categories
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MR imaging protocol
Over 90% of all 193 institutions performed an MR imaging
protocol consisting of the following structural sequences: T1-
weighted (100%, of which 72.5% in 3D and 27.5% 2D acqui-
sition), FLAIR (96.4%), T2-weighted (93.8%), T2*-weighted
GRE or susceptibility-weighted imaging (SWI) (92.2%) and
diffusion-weighted imaging (91.2%). Only 13% of institutions
routinely performed T1-weighted imaging post-gadolinium-
contrast-based agent administration. Coronal reformats for hip-
pocampal assessment were made routinely in 80.9% of the 193
centres, usually (62.2%) by radiographers, and in 27.5% by
radiologists themselves.
With respect to advanced imaging, only 48 (25%) of insti-
tutions performed any type of advanced imaging in routine
diagnostic workup of dementia patients. Of these, the most
frequent were ASL (n = 25), DTI (n = 23), spectroscopy (n =
15), resting-state fMRI (n = 12) or dynamic contrast-enhanced
(DCE)/dynamic susceptibility contrast (DSC) perfusion (n =
7). Primary reasons mentioned not to perform advanced im-
aging were that clinicians do not request it (57.9%) because it
is too time-intensive (59.7%), the sequences are not available
(30.1%) or post-processing software is not available (23.5%—
multiple answers possible).
More detailed reasons are shown in Supplementary Fig. 1.
Image interpretation: use of semi-quantitative rating scales
In 144 (74.6%) of all institutes, visual rating scales were used for
scan interpretation. This proportion was slightly higher in non-
academic (79.2%) than academic (69.3%) institutes. Reasons to
not use rating scales (in 49 (25.4%) of institutes overall) were
mainly that radiologists are not trained to use these (57.1%), that
clinicians do not ask for this information (28.6%) or the use of
these scales is considered too time-intensive (26.5%). Only
16.3% of the 49 non-users indicated that scales were ‘not useful’.
Among the 144 institutes who used rating scales, Fig. 4 pre-
sents which types of scales were used and with what frequency.
The survey questioned respondents whether they used each scale
‘always’ (in every scan), ‘regularly’ (inmore than 50%of scans),
‘sometimes’ (in less than 50% of scans) or ‘never’. Most fre-
quently used scales were white matter hyperintensity rating
scales (used regularly or always in 81.9%) and the medial tem-
poral atrophy (MTA) scale (used regularly or always in 81.3%).
The global cortical atrophy (GCA) scale (53.4%) and the
Koedam scale for posterior atrophy (32.6%) were less often
applied. The relative frequency of use of visual rating scales
did not differ between the academic and non-academic setting.
Confidence in use of these rating scaleswas again not different
between academia and general hospitals, with 16.7% expressing
high confidence and 50.7% reasonable confidence. Still, about a
third of those using rating scales (n= 144 respondents) did not
feel entirely confident (29.2%) or not confident at all (3.5%).
Use of quantitative information
Quantitative information, such as volumetric data, were used
regularly in only 5.7% of the 193 centres, and in specific cases
in 18.1% of institutes. Thus, in 147 (76.2%) institutes, volu-
metric information was never used. These proportions were
similar for academic versus non-academic institutes.
Reasons not to perform quantitative evaluation were pri-
marily the lack of access to software algorithms (70.1%) and
the feeling that it would be too time-intensive (51.7%) (see
more details in Supplementary Fig. 2).
Regarding the type of volumetric data used among those 46
institutes who did so regularly or in specific cases, hippocam-
pal volume (in 39 (84.8%)) and total brain volume (in 30
(65.2%)) were most frequently measured, followed by white
and grey matter volume (in 22 (47.8%)) and lobar volumes (in
17 (37%)).White matter hyperintensity volumewas measured
in only 21.7% of volumetric assessments.
Of the 46 centres that sometimes or regularly used volu-
metric data, 25 (54.3%) used normative reference data (e.g.
percentile curves) to compare individual patients to. These
reference data were derived from a large and heterogeneous
range of data sources (varying from own samples, manufac-
turer provided or available open-access datasets).
Most of these 46 centres used the freely available
FreeSurfer software (43.5%) for volumetric processing,
followed at a distance by NeuroQuant (17.4%), AppMRI hip-
pocampus volume analyser (15.2%) and Icometrix (4.3%).
Structured reporting
Structured reports were used in 54 (28.0%) of the 193 insti-
tutes, without differences between the academic and non-
academic setting. The top reason not to use a structured report
(in n = 139 institutes) was because radiologists do not find it
useful (33.1%), followed by incompatibility with the speech
recognition software (26.5%), time intensiveness (21.6%) and
the fact that clinicians do not request structured reports
(16.5%). In free text, 22 respondents (16%) mentioned that
they are not used to it or do not have templates available.
Communication with clinicians
On the imaging request form, a detailed information regarding
symptoms and the suspected diagnosis was provided by clini-
cians in only 57 institutes (29.5%), whereas only generic in-
formation ("query: dementia?") was provided in 130 (67.4%),
and no information was provided in four (2.1%). These per-
centages did not differ substantially between academia (65%
only generic information) and general institutions (73% only
generic information).
In the conclusion of their radiological report, 60 (31.1%) of
all respondents always indicated whether imaging findings
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support a diagnosis of dementia (and which subtype), whereas
108 (56%) only did so if the clinical diagnosis met the demen-
tia criteria. Thirteen percent (13%) never included a statement
on dementia in their conclusion. These numbers were equal
for academia and general institutes.
In 19.1% of institutes (n = 37), cases suspected of dementia
were always (4.1%) or regularly (more than 50% of new exams
in 15%) discussed in multidisciplinary meetings, whereas this
type of communication among specialists occurred ‘infrequent-
ly’ (less than 50% of patients) in 48.2% and ‘never’ in 32.6% of
centres. If multidisciplinary meetings were held, these were
primarily attended by neurologists (86.9%), radiologists
(83.8%), neuropsychologists (41.5%) and geriatricians
(41.5%). Psychiatrists were present in 30.8% of meetings; nu-
clear medicine physicians (15.4%), internists (9.2%), social
workers (10%) and researchers (8.5%) less often so.
Discussion on survey results and conclusions
Generalisability of results
The ESNR survey on imaging in dementia had a reasonable
number of responses (193 unique European centres), with a
good geographical spread including Eastern-Europe. We
should consider however that the low response rate (less than
Fig. 4 Use of visual rating scales. Pie charts show the frequency of use of each visual rating scale over all 193 institutes. Colours represent categories, and
size of the coloured areas represents % of positive responses
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5% of all invitations) will have led to selection bias, likely
towards an overrepresentation of those who are very active
and potentially have more expertise in this field. Indeed, the
majority of respondents were subspecialty-trained neuroradiol-
ogists and working in academic centres, seeing roughly five
scans per week for patients with dementia. Referrals tended to
be from dedicated memory centres, though in non-academic
centres, this was balanced with primary care referrals. We tried
to take the academic overrepresentation into account by strati-
fying several results for academic versus non-academic centres
and found that these did not differ, pointing towards
generalisability and representativeness. Also, the response rate
in this survey was very similar to an earlier pan-European sur-
vey conducted by the ESNR on glioma imaging [19]. Overall,
we feel that the responses provide a reasonably realistic picture
of neuroradiology practice for dementia in Europe.
Imaging modality and protocol for dementia
The imaging modality of choice among the survey respon-
dents clearly is MRI and, in those cases where CT was used,
motivation varied and included reasons such as limited access
to MRI or lack of clinical impact. Some respondents also
reported that the information obtained with CT is sufficient,
which is indeed justified for exclusion of other treatable
causes of cognitive impairment, and to a certain extent also
for atrophy patterns and more extensive vascular pathology
when using multi-detector CT with coronal and sagittal
reformats [20]. Yet, it should be noted that pathology such
as microbleeds, areas of diffusion restriction, and more subtle
patterns of vascular lesions (white matter pathology) and cor-
tical atrophy are better evaluated on MRI.
There was very high convergence on the MR sequences
used, with over 90% of respondents conducting the earlier
suggested minimum set of MR imaging sequences for the
evaluation of memory clinic patients (Box 1) [3, 4]. This in-
dicates that MR imaging among the European centres that
participated in the survey is already fairly homogeneous and
meets current acceptable standards in the field.
Box 1. Proposed minimum MR imaging protocol for de-
mentia imaging (adapted from [3, 4])
There was a limited use among survey respondents of ad-
vanced sequences, such as DTI and fMRI, in the majority due
to lack of interest among clinicians or radiologists (> 70% of
non-users), which is probably due to the lack of proven diag-
nostic performance or clinical impact as well as time inten-
siveness of the acquisition and post-processing in relation to
lack of reimbursement. ASL was used most frequently, prob-
ably reflecting its potential to replace fluorodeoxyglucose
(FDG)-PET [21] while being non-invasive. In addition to un-
certain value of many of the advanced sequences, prolonged
acquisition times and lack of tools/support to interpret the data
were hurdles that were mentioned by the survey respondents.
Inter-vendor differences in acquisition and analysis methods
likely play a role as well in the low rates of implementation of
advanced sequences.
Interpretation of scans
Interpretation of MRI scans in patients with dementia was
often (75% of all institutes) supported by the use of visual
rating scales which were used even more often by non-
academic centres. The most popular scales used were the
MTA for hippocampal and medial temporal involvement (re-
lated to Alzheimer’s disease) and the Fazekas scale for white
matter lesions of presumed cerebrovascular origin; both can
be applied to CTaswell [20]. Less frequently used were scales
for GCA and posterior atrophy (as can be seen in younger-
onset AD patients). Most respondents felt quite comfortable in
applying the visual rating scales, although there clearly is a
need for further training [15]. Although cut-off values for
abnormality are age (and sex)-dependent [22], visual rating
scales perform well in discriminating major dementing disor-
ders [14] and have good inter-observer variability [23]. Box 2
summarises the most frequently used visual rating scales.
Box 2. Frequently used visual rating scales
Routinely:
• MTA scales to describe hippocampal atrophy
• GCA to describe amount of global atrophy per lobe as well as any
asymmetry
•White matter hyperintensity scales (the Fazekas or ARWMC) for burden
of vascular pathology
Upon indication:
• Posterior atrophy scale (the Koedam scale) (and other regional
descriptors) (e.g. in suspected PCA and FTD)
GCA, global cortical atrophy; MTA, medial temporal atrophy; PCA, pos-
terior cortical atrophy; FTD, frontotemporal dementia; ARWMC, age-
related white matter changes
Use of volumetry in image interpretation: future
development?
Quantitative methods such as MR volumetry are currently
mainly used in research settings. As indicated in our survey,
• Sagittal 3D T1-weighted with sagittal and oblique/coronal reformats for
evaluation of cortical atrophy and hippocampal atrophy.
• Sagittal 2D axial FLAIR or 3D FLAIR with axial reformats for
evaluation of white matter pathology and infarcts.
• Axial T2-weighted for evaluation of non-neurodegenerative pathology
and infratentorial or thalamic infarcts.
•Axial T2*-weighted gradient echo or SWI for evaluation ofmicrobleeds
and macrohaemorrhage.
• Axial DWI for evaluation of acute ischemia or diffusion restriction in
Creutzfeld-Jakob disease.
• Routine administration of contrast agent should not be applied.
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only 5.7% of centres performed volumetric analyses on a reg-
ular basis, despite the fact that for example voxel-based mor-
phometry (VBM) was introduced already in 2000 [24], and
more user-friendly automated segmentation algorithms such
as FreeSurfer were introduced over 20 years ago.
Theoretical advances of implementation of volumetry are its
potentially higher sensitivity to subtle changes, yielding an ear-
lier detection of abnormality, an objective observer-independent
assessment and higher sensitivity to change over time, e.g. in
clinical trials. Yet, evidence from clinical practice supporting
these advantages is still scarce and not unequivocal [25–29].
Main hurdles identified by the respondents were the limited
availability of software, lack of time to use (offline) workstations
and difficulties in the interpretation. The lack of transition of
volumetric techniques into clinical routine is in our opinion fur-
thermore mainly due to key issues that are common to the in-
troduction of new biomarkers. These comprise lack of
standardisation, lack of validation, concerns about specificity
and the difficulty to translate research findings on a group level
to the individual patient. For example, with respect to hippocam-
pal volumetry, the rate of atrophy of AD patients is around
4.25% per year, yet only 1.25% per year in controls, i.e. 3%
difference for a follow-up imaging of 1 year [30]. To be able to
detect these small differences and apply these findings in a clin-
ical setting would call for standardisation of image acquisition
(field strength, vendor type, imaging parameters) as, for exam-
ple, done in ADNI [31]. In addition, in a single time point
setting, the use of reference populations or control groups rep-
resentative for the population an individual patient was derived
from is needed. Likewise, there are multiple software analysis
tools andmultiple data analysis parameters whichmay influence
the obtained results.
Communication between referring clinicians
and radiologists
In most instances, referrals were not accompanied by detailed
clinical information and only a minority of respondents par-
ticipated regularly in multidisciplinary meetings where such
information would have been available. This most likely re-
flects the previous practice of performing structural imaging in
suspected dementia only with the aim to exclude a surgical
lesion. The role of neuroimaging in dementia has however
changed importantly with imaging being incorporated in re-
search and diagnostic criteria of several dementia subtypes [5,
7]. This stresses the need for close communication between
referring clinicians and radiologists to obtain the most valu-
able information with respect to differential diagnosis.
In contrast, a general lack of clinical information may also
drive a radiologist to scrutinise the images in a systematic fash-
ion (rather than to look for a confirmatory finding) and may be
more objective than being potentially misled by the clinical
information. For example, in the clinical diagnosis of AD, about
a third of cases cannot be confirmed and finding some degree of
hippocampal atrophy could be misinterpreted when other diag-
noses are not systematically considered (e.g. FTD).
Participation of multidisciplinary team (MDT) meetings
was variable, although if these happened, radiologists were
frequently included. Recognising that MDT meetings require
time for preparation and attendance, we strongly recommend
radiologists to participate, as it will allow them to address
specific clinical information that may have arisen after the
request form was issued or the patient was examined in more
detail and the radiological findings can now be interpreted in
light of additional laboratory (e.g. CSF) findings. Although
numbers are not known for dementia MDT meetings, studies
from the field of oncology show that radiological input during
MDT meetings results in direct influence on patient manage-
ment in up to 20% of discussed cases [32, 33]. MDTmeetings
are also important to generate feedback on the quality of the
radiology reports and provide a mechanism to verify the ac-
curacy of the conclusions and the appropriateness of the word-
ing of reports. Finally, they provide an excellent training en-
vironment for younger colleagues.
Structured analysis and reporting
Literature points towards the fact that semi-structured
reporting may help to more systematically evaluate scans,
remove ambiguity, lead to more clarity towards clinicians
and facilitate research [34]. Yet in the majority of responding
institutes (72% out of 193), radiologists did not apply struc-
tured reporting in dementia imaging, with as most common
reasons not being supported by dictation software, being time-
consuming or not helpful. Despite this, the frequent use of
visual rating scales indicates there at least is a semi-
structured approach to the interpretation of images. In fact,
use of a standard set of visual rating scales (see Box 2) and
measurements is a way to structure the analysis path and build
the report systematically. In addition, the use of a common
language may further be facilitated by the use of visual rating
scales, which are more objective than subjective terms such as
‘mild’, ‘appreciable’ or ‘significant’. Interestingly, the use of
semi-quantitative scales seemed to be adopted more widely in
non-academic centres for reasons not further explored in the
survey.
Finally, a report should always be placed in context of the
provided information and question. The conclusion can men-
tion whether there is neurodegeneration (and vascular) pathol-
ogy beyond expectation for ageing, but, unless specifically
asked to confirm a specific diagnosis, should only provide a
possible differential diagnosis, to avoid anxiety and confusion
among referrers and patients. This caveat becomes increasing-
ly important as patients are getting direct access to reports
through electronic health records and may even read the report
before seeing the clinician.
640 Neuroradiology (2019) 61:633–642
Box 3 indicates a suggested structure for reporting in de-
mentia imaging [3, 4].
Box 3. Suggested structure for reporting in dementia imag-
ing (adapted from [3, 4])
Conclusion and future outlook
Given the survey findings, we conclude that current practice in
dementia imaging is fairly homogeneous across Europe, in
terms of image acquisition and image interpretation. With re-
spect to protocol set-up, relatively easy adaptation towards the
best clinical practice recommendations can be expected, al-
though some variations throughout Europe are likely to remain,
depending on reimbursement strategies, practical and logistical
setups and availability of scanning facilities. Several hurdles
have been identified through the survey that may help progress
the field further. These mainly lie in the areas of training on the
use of visual rating scales, translation of research findings (ad-
vanced imaging) to a clinical setting, implementation of volu-
metric assessment, structured reporting and communication.
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